Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ...
Corcept Therapeutics Inc (CORT) posted $340.5 million in Q3 2026 revenue on explosive oncology growth, reiterated its full-year guidance, and now awaits a December 17 FDA decision on relacorilant. Related Stocks: CORT ,